Clinical Trial Imaging Market (By Service: Clinical Trial Design and Consultation Services, Reading and Analytical Services, Project and Data Management, System and Technology Support Services; By Modality: Computed Tomography, Ultrasound, Magnetic Resonance Imaging, Positron Emission Tomography, Echocardiography, X-Ray, Other Modalities; By End-Use) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Clinical Trial Imaging Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Clinical Trial Imaging Market, by Service, 2024-2033
8.1.1 Clinical Trial Design and Consultation Services
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Reading and Analytical Services
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Project and Data Management
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. System and Technology Support Services
8.1.4.1. Market Revenue and Forecast (2021-2033)
9.1. Clinical Trial Imaging Market, by Modality, 2024-2033
9.1.1. Computed Tomography
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Ultrasound
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Magnetic Resonance Imaging
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Positron Emission Tomography
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Echocardiography
9.1.5.1. Market Revenue and Forecast (2021-2033)
9.1.6. X-Ray
9.1.6.1. Market Revenue and Forecast (2021-2033)
9.1.7. Other Modalities
9.1.7.1. Market Revenue and Forecast (2021-2033)
10.1. Clinical Trial Imaging Market, by End-Use, 2024-2033
10.1.1. Pharmaceutical Companies
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Medical Device Manufacturers
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Academic and Government Research Institutes
10.1.3.1. Market Revenue and Forecast (2021-2033)
10.1.4. Biotechnology Companies
10.1.4.1. Market Revenue and Forecast (2021-2033)
10.1.5. Contract Research Organizations
10.1.5.1. Market Revenue and Forecast (2021-2033)
10.1.6. Other End-Users
10.1.6.1. Market Revenue and Forecast (2021-2033)
11.1. North America
11.1.1. Market Revenue and Forecast, by Service (2021-2033)
11.1.2. Market Revenue and Forecast, by Modality (2021-2033)
11.1.3. Market Revenue and Forecast, by End-Use (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Service (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Modality (2021-2033)
11.1.4.3. Market Revenue and Forecast, by End-Use (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Service (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Modality (2021-2033)
11.1.5.3. Market Revenue and Forecast, by End-Use (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Service (2021-2033)
11.2.2. Market Revenue and Forecast, by Modality (2021-2033)
11.2.3. Market Revenue and Forecast, by End-Use (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Service (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Modality (2021-2033)
11.2.4.3. Market Revenue and Forecast, by End-Use (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Service (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Modality (2021-2033)
11.2.5.3. Market Revenue and Forecast, by End-Use (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Service (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Modality (2021-2033)
11.2.6.3. Market Revenue and Forecast, by End-Use (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Service (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Modality (2021-2033)
11.2.7.3. Market Revenue and Forecast, by End-Use (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Service (2021-2033)
11.3.2. Market Revenue and Forecast, by Modality (2021-2033)
11.3.3. Market Revenue and Forecast, by End-Use (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Service (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Modality (2021-2033)
11.3.4.3. Market Revenue and Forecast, by End-Use (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Service (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Modality (2021-2033)
11.3.5.3. Market Revenue and Forecast, by End-Use (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Service (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Modality (2021-2033)
11.3.6.3. Market Revenue and Forecast, by End-Use (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Service (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Modality (2021-2033)
11.3.7.3. Market Revenue and Forecast, by End-Use (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Service (2021-2033)
11.4.2. Market Revenue and Forecast, by Modality (2021-2033)
11.4.3. Market Revenue and Forecast, by End-Use (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Service (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Modality (2021-2033)
11.4.4.3. Market Revenue and Forecast, by End-Use (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Service (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Modality (2021-2033)
11.4.5.3. Market Revenue and Forecast, by End-Use (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Service (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Modality (2021-2033)
11.4.6.3. Market Revenue and Forecast, by End-Use (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Service (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Modality (2021-2033)
11.4.7.3. Market Revenue and Forecast, by End-Use (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Service (2021-2033)
11.5.2. Market Revenue and Forecast, by Modality (2021-2033)
11.5.3. Market Revenue and Forecast, by End-Use (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Service (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Modality (2021-2033)
11.5.4.3. Market Revenue and Forecast, by End-Use (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Service (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Modality (2021-2033)
11.5.5.3. Market Revenue and Forecast, by End-Use (2021-2033)
12.1. IXICO plc
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Intrinsic Imaging
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Resonance Health
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. BioTelemetry
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Navitas Life Sciences
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. ProScan Imaging
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Cardiovascular Imaging Technologies
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Medpace
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Radiant Sage LLC
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Biomedical Systems Corp
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample